IMVARIA is a pioneering health tech company specializing in AI-driven digital biomarker solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease, reducing the need for invasive biopsy testing. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates a centralized AI Lab that utilizes automated, machine-learning algorithm technology to transform clinical decision-making into data science.

IMVARIA develops FDA-authorized AI software solutions such as Fibresolve, which aids in the non-invasive diagnosis of lung fibrosis and idiopathic pulmonary fibrosis, and ScreenDx, an AI-powered tool that assesses imaging data for interstitial lung disease. The company is also advancing Bronchosolve, an AI diagnostic solution for lung cancer diagnosis currently available for research purposes. IMVARIA collaborates with leading institutions like Mayo Clinic and Medical Horizons to expand its reach and enhance the understanding of cancer and lung diseases through AI digital biomarkers.